1-15 of 15
Patrick Henrick
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors

Tatyana Feldman, Enrica Marchi, Stephen D. Smith, Adam J. Olszewski, Auris O Huen, Zachary D. Epstein-Peterson, Don A. Stevens, Alexander N. Starodub, Eric J. Feldman, Cristina P Rodriguez, John C. Reneau, Jonathan E. Brammer, Ahmad H. Mattour, Lauren C. Pinter-Brown, Rachelle Perea, Patrick Henrick, Joyoti Dey, Alyssa Fasciano, Rahul Karnik, Sagar Agarwal, Ashwin Gollerkeri, Jared Gollob, Aditi Shastri, Stefan K. Barta
Journal: Blood
Blood (2024) 144 (Supplement 1): 4433.
https://doi.org/10.1182/blood-2024-210301
Published: 2024
Journal Articles

Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Jennifer Kimberly Lue, Don A. Stevens, Michael E. Williams, Jason Westin, Reggie Ewesuedo, Alice McDonald, Sagar Agarwal, Patrick Henrick, Rachelle Perea, Jared Gollob
Journal: Blood
Blood (2022) 140 (Supplement 1): 12143–12144.
https://doi.org/10.1182/blood-2022-170151
Published: 2022
Journal Articles

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Jorge E. Cortes, MD, Eunice S. Wang, MD, Justin M. Watts, MD, Sangmin Lee, MD, Maria R. Baer, MD, Kim-Hien Dao, DO, PhD, Shira Dinner, MD, Jay Yang, MD, William B. Donnellan, MD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Christian Recher, MD PhD, Patrick Kelly, MD, Jennifer Sweeney, Julie Brevard, Patrick Henrick, Sanjeev Forsyth, Sylvie Guichard, Hesham Mohamed, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 674.
https://doi.org/10.1182/blood-2019-124360
Published: 2019
Journal Articles

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Justin M. Watts, MD, Maria R. Baer, MD, Jay Yang, MD, Thomas Prebet, MD PhD, Sangmin Lee, MD, Gary J. Schiller, MD, Shira Dinner, MD, Arnaud Pigneux, Pau Montesinos, MD PhD, Eunice S. Wang, MD, Karen Seiter, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Stephane De Botton, Montserrat Arnan Sangerman, William B. Donnellan, MD, Brian A Jonas, MD PhD, Paul Brent Ferrell, Jr., MD, Kim-Hien Dao, DO, PhD, Patrick Kelly, MD, Jennifer Sweeney, Sanjeev Forsyth, Sylvie Guichard, Julie Brevard, Patrick Henrick, Hesham Mohamed, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 231.
https://doi.org/10.1182/blood-2019-123920
Published: 2019
Journal Articles

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients

Romanos Sklavenitis-Pistofidis, Marzia Capelletti, Chia-Jen Liu, Mairead Reidy, Oksana Zavidij, Daisy Huynh, Patrick Henrick, Alexandra Savell, Kaitlen Reyes, Bradley Rivotto, Mark Bustoros, Adriana Perilla-Glen, Lorenzo Trippa, Jorge J. Castillo, Steven P. Treon, Irene M. Ghobrial
Journal: Blood
Blood (2018) 132 (24): 2608–2612.
https://doi.org/10.1182/blood-2018-07-863241
Published: 2018
Journal Articles

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Chia-jen Liu, MD, Irene M. Ghobrial, MD, Mark Bustoros, MD, Kaitlen Reyes, NP, Kalvis Hornburg, BA, Ashraf Z. Badros, MD, James J. Vredenburgh, MD, Adam Boruchov, MD, Jeffrey V Matous, MD, Aaron Caola, BS, Bradley Rivotto, BS, Alexandra Savell, BS, Patrick Henrick, BS, Claudia E. Paba-Prada, MD, Robert L. Schlossman, MD, Jacob Laubach, MD, Jacalyn Rosenblatt, MD, Andrew J Yee, MD, Omar Nadeem, MD, Rodrigo O. Maegawa, MD, Andrzej Jakubowiak, MD PhD, Saad Z. Usmani, MD, Manisha Bhutani, MD, Joseph Cappuccio, BS, Brianna Berrios, BS, Kimberly Noonan, NP, Oksana Zavidij, PhD, Tarek H Mouhieddine, MD, Cody J Boehner, Carl-Jannes Neuse, Karma Ziad Salem, MD, Mairead Reidy, PhD, Jihye Park, PhD, Michael Agius, PhD, Mahshid Rahmat, PhD, Salomon Manier, MD PhD, Divaya Bhutani, MD, Jeffrey A Zonder, MD, Nikhil Munshi, MD, Daniel Auclair, PhD, Kenneth Anderson, MD, Paul Richardson
Journal: Blood
Blood (2018) 132 (Supplement 1): 154.
https://doi.org/10.1182/blood-2018-154
Published: 2018
Journal Articles

Progression Risk-Based Classification of Asymptomatic Waldenström Macroglobulinemia

Mark Bustoros, MD, Romanos Sklavenitis-Pistofidis, MD, Chia-jen Liu, MD, Efstathios Kastritis, MD, Geoffrey Fell, PhD, Kalvis Hornburg, BA, Carl-Jannes Neuse, Patrick Henrick, BS, Catherine R. Marinac, PhD, Adriana Perilla-Glen, Alexandra Savell, BS, David Liu, MD MPH, MS, Amir Yosef, MD, Bradley Rivotto, BS, Jenny Soiffer, Henry Dumke, BS, Cody J Boehner, Kaitlen Reyes, NP, Kimberly Noonan, NP, Robert J. Soiffer, MD, Steven P Treon, MD PhD FRCP, Jorge J. Castillo, MD, Meletios A Dimopoulos, MD, Irene M. Ghobrial, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 150.
https://doi.org/10.1182/blood-2018-99-114324
Published: 2018
Journal Articles

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Mark Bustoros, MD, Chia-jen Liu, MD, Kaitlen Reyes, NP, Kalvis Hornburg, BA, Kathleen Guimond, RN, Rachel Styles, Alexandra Savell, BS, Brianna Berrios, BS, Diane Warren, Henry Dumke, BS, Bradley Rivotto, BS, Patrick Henrick, BS, Emily Scranton, NP, Houry Leblebjian, PharmD, Kirsten Meid, MPH, Robert L. Schlossman, MD, Nikhil Munshi, MD, Jacob Laubach, MD, Kenneth C. Anderson, MD, Paul Richardson, Irene M. Ghobrial, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 804.
https://doi.org/10.1182/blood-2018-99-117871
Published: 2018
Journal Articles

A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Chia-Jen Liu, MD PhD, Raymond P. Perez, MD, Paul Richardson, Kenneth C. Anderson, MD, Jacob Laubach, MD, Patrick Henrick, BS, Alexandra Savell, BS, Kaitlen Reyes, NP, Kalvis Hornburg, BA, Stacey Chuma, BSN, Peter Sabbatini, Pamela S. Becker, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3263.
https://doi.org/10.1182/blood-2018-99-117773
Published: 2018
Journal Articles

Impact of Bone Marrow Biopsy on Risk Stratification of Low-Risk IgG MGUS Patients

Mark Bustoros, Eftathios Kastritis, Chia-Jen Liu, MD PhD, Nikolaos Kanellias, David Liu, MD MPH, MS, Maria Gavriatopoulou, Adriana Perilla Glen, Maria Roussou, Patrick Henrick, BS, Magdalini Migkou, Alexandra Savell, BS, Kimberly Noonan, NP, Kaitlen Reyes, NP, Bradley Rivotto, BS, Houry Leblebjian, PharmD, Claudia Paba-Prada, MD, Dimitrios C. Ziogas, Jacob Laubach, MD, Robert L. Schlossman, MD, Kenneth C Anderson, MD, Paul G Richardson, MD, Irene M Ghobrial, MD, Meletios A. Dimopoulos
Journal: Blood
Blood (2017) 130 (Supplement 1): 5397.
https://doi.org/10.1182/blood.V130.Suppl_1.5397.5397
Published: 2017
Journal Articles

Next Generation Sequencing Identifies Smoldering Multiple Myeloma Patients with a High Risk of Disease Progression

Mark Bustoros, Jihye Park, PhD, Karma Ziad Salem, MD, Chia-Jen Liu, MD PhD, Marzia Capelletti, PhD, Daisy Huynh, BS, MS, Yu-Tzu Tai, PhD, Tarek H Mouhieddine, MD, Samuel Freeman, Gavin Ha, PhD, Justin Rhoades, Sarah Reed, Gregory Gydush, Denisse Rotem, Adriana Perilla Glen, Patrick Henrick, BS, Aaron Caola, Bradley Rivotto, BS, Alexandra Savell, BS, Kimberly Noonan, NP, Kaitlen Reyes, NP, Antonio Sacco, Cody J Boehner, Houry Leblebjian, PharmD, David Liu, MD MPH, MS, Elizabeth A Morgan, MD, Aldo M. Roccaro, Claudia Paba-Prada, MD, Eliezer Van Allen, MD, Christopher Love, Viktor Adalsteinsson, PhD, Jacob Laubach, MD, Robert Schlossman, MD, Nikhil Munshi, MD, Paul G Richardson, MD, Kenneth C Anderson, MD, Shaji K Kumar, MD, Gad Getz, PhD, Irene M Ghobrial, MD, Salomon Manier, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 392.
https://doi.org/10.1182/blood.V130.Suppl_1.392.392
Published: 2017
Journal Articles

Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

Jacob P. Laubach, MD, Noopur Raje, MD, Andrew J. Yee, MD, Philippe Armand, MD PhD, Robert L. Schlossman, MD, Jacalyn Rosenblatt, MD, Michael G. Martin, MD, Craig Reynolds, MD, Kenneth H. Shain, MD PhD, Ira Zackon, MD, Laura V. Stampleman, MD, Emily Lai, BS, Aaron M. Caola, BS, Joseph M. Cappuccio, BS, Bradley Rivotto, BS, Kaitlen Reyes, DNP, Alexandra Savell, BS, Patrick Henrick, BS, Tillman Pearce, MD, Damian Handisides, Stew Kroll, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Irene M. Ghobrial, MD
Journal: Blood
Blood (2016) 128 (22): 2122.
https://doi.org/10.1182/blood.V128.22.2122.2122
Published: 2016
Journal Articles

Whole Exome Sequencing and Targeted Sequencing Reveal the Heterogeneity of Genomic Evolution and Mutational Profile in Smoldering Multiple Myeloma

Karma Salem, MD, Jihye Park, PhD, Claudia Freymond, MSc, Marzia Capelletti, PhD MMSc, Daisy Huynh, BS, MS, Antonio Sacco, BS, RN, Adriana Perilla Glen, MBA, Aaron M. Caola, BS, Patrick Henrick, BS, Eliezer Van Allen, MD, David Liu, MD, Aldo M. Roccaro, MD PhD, Nikhil C Munshi, MD, Gad Getz, PhD, Irene M. Ghobrial, MD, Salomon Manier, MD
Journal: Blood
Blood (2016) 128 (22): 237.
https://doi.org/10.1182/blood.V128.22.237.237
Published: 2016
Journal Articles

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Irene M. Ghobrial, MD, Ashraf Z Badros, MD, James J. Vredenburgh, MD, Jeffrey Matous, MD, Aaron M. Caola, BS, Alexandra Savell, Patrick Henrick, Claudia E. Paba-Prada, MD, Robert L. Schlossman, MD, Jacob P. Laubach, MD, Jacalyn Rosenblatt, MD, Andrew Yee, Jeffrey S. Wisch, MD, Charles M. Farber, MD PhD, Rodrigo O. Maegawa, MD, Saad Z Usmani, MD FACP, Joseph Cappuccio, Bradley Rivotto, BS, Kimberly Noonan, NP, Kaitlen Reyes, DNP, Nikhil C. Munshi, MD, Kenneth C. Anderson, Paul Richardson, MD
Journal: Blood
Blood (2016) 128 (22): 976.
https://doi.org/10.1182/blood.V128.22.976.976
Published: 2016
Journal Articles

Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Kenneth H. Shain, MD, Jacob Laubach, MD, Patrick Henrick, James Vredenburg, MD, Pamela Crilley, MD, Michael Constantine, MD, Caroline Block, MD, Frank G. Basile, MD, Joseph Cappuccio, Abdel Kareem Azab, BPharm, PhD, Emily Lai, Aaron Caola, Ranjit Banwait, Alexandra Savell, Nikhil C. Munshi, MD, Claudia E. Paba-Prada, MD, Robert L. Schlossman, MD, Stacey Chuma, BSN, Kimberly Noonan, NP, Kenneth C. Anderson, MD, Paul G. Richardson, MD
Journal: Blood
Blood (2015) 126 (23): 4256.
https://doi.org/10.1182/blood.V126.23.4256.4256
Published: 2015